saxenda glp-1 diabetes market impact Size, Share Saxenda Headed to the Weight

Inphase 3 clinical trials (SURPASS 1-5), the dose-dependent efficacy and safety of tirzepatide were assessed by once-weekly subcutaneous injection (5mg, 10mg, and 15 mg), as monotherapy or combination therapy, in individuals with T2DM

The most common designs are observational studies

Eli Lillys first nine months of 2025 underscored the scale of the GLP-1 surge: Mounjaro and Zepbound generated $39.5 billion in revenue and surpasses Mercks Keytruda as the worlds best-selling medicine[5]

PlexusDx provides compounded semaglutide injections from licensed pharmacies with proven efficacy

Invest in clinical development that supports new, high-need indications that can improve the brands value proposition, especially in restrictive channels like Medicare

No judgment